Innovative Framework for Analyzing Genetic Data

Technology #ua15-065

Questions about this technology? Ask a Technology Manager

Download Printable PDF

License this Technology
N-of-1-pathways: Personal ‘omics analytic software for precision medicine
Vincent Gardeux
Research Assistant Professor, Medicine
Ikbel Achour
Director, Precision Health, Medicine
Yves Lussier
Associate Director, Medicine
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

N-of-1-pathways: Personal ‘omics analytic software for precision medicine


*****License must be requested by Faculty***** 




N-of-1-pathways is the first analytic framework designed for personal ‘omics profiling with its initial application intended for personal transcriptome interpretation. Capable of analyzing RNA-seq, microarray, or any technology measuring genome expression, N-of-1-pathways provides a personal, biological mechanistic profile conceived to predict clinical outcomes, to analyze response to therapy, and to monitor disease progression - one patient at a time.




Moving from cohort to single-subject based analytics: N-of-1-pathways uncovers dysregulated pathways at the single patient resolution (individual level) taking into account that each individual genetic blueprint and genomic activities are unique and cannot be evaluated based on population-level analysis.


Moving from static to dynamic transcriptome-based analytics: N-of-1-pathways is based on the analysis of paired transcriptomes derived from a subject’s tissue or cells (liquid or solid biopsies). Example pairs include healthy and tumoral, before and after therapy, or pre and post in vitro stimulation. Using a single pair of samples, N-of-1-pathways uncovers the dynamic whole genome expression changes from one physiological state to another, reflective of a more accurate response to therapy or stimulation.




The emergence of precision medicine ushered in a groundbreaking era in medicine with the opportunity for tailoring medical treatment to each individual based on his/her own genome blueprint and biological activities. Genome expression changes are recurrent and unique to each individual as well as mirror individual disease progression or differences in how one responds to therapy and environmental stimulus. Current transcriptome analytic tools uncovering common pathways extrapolated to larger populations overlook differences between patients. Further, 99% of molecular biomarkers derived from predictors of large patient samples fail to be reproducible. Therefore, methods are required to detect and analyze specific individual response to therapy or tissue specific-dependent mechanisms leading to optimal molecular biomarker discovery and testing, thus providing tailored and more accurate therapeutic options.




In 2013, the personalized precision medicine market, particularly molecular diagnostics, was valued at $4.4 billion and is projected to reach $8.2 billion by 2020 with a compound annual growth rate of 8.7 percent. The market is in its growth phase. The US government strongly supports funding precision medicine, motivating many companies to initiate new projects in this field as encouraged, since 2015, by President Obama’s Precision Medicine Initiative of the White House. The aging population is continuing to grow at a rapid pace, resulting in more individuals looking for better quality of care and requiring tailored medications with improved accuracy. The application of the N-of-1-pathways aims to improve diagnostic capability over current procedures. This will be of value for companies looking to create a platform for this technology while increasing accuracy and efficacy of clinical trials and developing specific medical diagnostic tests. 




•       N-of-1-pathways software for academic use:  $0.00/year

•       N-of-1-pathways software for small to large Entities: customized fee/year*

*Fees are subject to change and will be associated to new application and features added to N-of-1-pathways analytic framework.


For more information, please visit the Lussier lab page: